AstraZeneca to pull breast cancer and endometriosis drug Zoladex from Australian market in November
By
Krishani Dhanji
Summary
AstraZeneca is removing the breast cancer and endometriosis drug Zoladex from Australia's Pharmaceutical Benefits Scheme (PBS) and private market starting November, potentially leaving thousands of women without access to this vital treatment. Existing patients will have an additional six months of access. Experts warn of increasing delays in listing other critical breast cancer drugs on the PBS, which may be linked to US policy changes and global uncertainty.
Source
bskyAstraZeneca to pull breast cancer and endometriosis drug Zoladex from Australian market in Novembertheguardian.comKey quotes
· 3 pulledThousands of women could be left without vital breast cancer and endometriosis medicine when AstraZeneca removes its treatment from the Pharmaceutical Benefits Scheme (PBS) and the private market, experts warn.
Zoladex will no longer be available in Australia from November, as the ABC first reported, but some existing patients will still be able to access it for an additional six months.
Breast Cancer Network Australia also says there have been increasing delays to list other critical breast cancer drugs on the PBS, which they fear is due to policy changes in the US and global uncertainty.
You might also wanna read
Could Ozempic Lower Breast Cancer Risk? What to Know
ELLE·4d ago
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·1mo ago
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
This article appears to be a medical education piece focused on breast cancer treatment strategies, specifically discussing patients progres
mdsc.pe·11d ago
Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration
Researchers at Florida A&M University have discovered that compounds called polyisoprenylated cysteinyl amide inhibitors can stop 90% of pan
sciencealert.com·2d ago
FDA Drug Regulator Accused of Targeting Former Business Associate's Pharmaceutical Company
The article discusses a scandal at the FDA involving a top drug regulator who allegedly used his position to target a former business associ
arstechnica.com·8mo ago
Pancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trials
Scientists gave a standing ovation at a Chicago conference for clinical trial results of daraxonrasib, a pancreatic cancer drug developed by
economist.com·2d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.